Viking Therapeutics Outlines $100 Million Average Quarterly Cash Burn Amid Clinical Pipeline Advancement
Viking Therapeutics (VKTX) reported progress across its clinical pipeline during the third quarter, highlighted by positive results from a maintenance dosing study within its obesity program. CEO Brian Lian noted that the company is advancing several key programs, including the Phase III SUNRISE and VANQUISH studies. The company expects an average quarterly cash usage of approximately $100 million as it continues to fund these late-stage clinical developments. This spending reflects the intensified capital requirements necessary to drive its metabolic and obesity drug candidates toward potential regulatory milestones.
Tickers: $VKTX
Topics: clinical trial results earnings call obesity drug pipeline